Evidence map›Paper›PMID 33266444›Full record

ArticlePharmaceutics2020

Targeting of the Pilosebaceous Follicle by Liquid Crystal Nanocarriers: In Vitro and In Vivo Effects of the Entrapped Minoxidil.

Massimo Fresta, Antonia Mancuso, Maria Chiara Cristiano, Konrad Urbanek, Felisa Cilurzo, Donato Cosco, Michelangelo Iannone, Donatella Paolino

Abstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Nanonutraceuticals: The New Frontier of Supplementary Food.Nanomaterials (Basel, Switzerland) · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Massimo FrestaDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", viale Europa, 88100 Germaneto (CZ), Italy.ORCID 0000-0001-8062-817X
Antonia MancusoDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", viale Europa, 88100 Germaneto (CZ), Italy.ORCID 0000-0002-0915-8643
Maria Chiara CristianoDepartment of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", viale Europa, 88100 Germaneto (CZ), Italy.
Konrad UrbanekDepartment of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", viale Europa, 88100 Germaneto (CZ), Italy.
Felisa CilurzoDepartment of Pharmacy, University of Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Italy.ORCID 0000-0001-7429-5591
Donato CoscoDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", viale Europa, 88100 Germaneto (CZ), Italy.ORCID 0000-0002-4898-0365
Michelangelo IannoneNational Council of Research (CNR), The Institute for Biomedical Research and Innovation, viale Europa, 88100 Germaneto (CZ), Italy.
Donatella PaolinoDepartment of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", viale Europa, 88100 Germaneto (CZ), Italy.ORCID 0000-0002-5223-9879

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The topical administration of active compounds represents an advantageous strategy to reach the various skin components as well as its appendages. Pilosebaceous follicles are skin appendages originating in the deeper skin layers. They are very difficult to target, and hence higher active dosages are generally required to achieve effective biological responses, thus favoring the rise of side effects. The aim of this work was to design a supramolecular colloidal carrier, i.e., a liquid crystal nanocarrier, for the selective delivery of active compounds into the pilosebaceous follicle. This nanocarrier showed mean sizes of ~80 nm, a good stability, a negative surface charge, and great safety properties. In vitro studies highlighted its ability to contain and release different substances and to successfully permeate the skin. Minoxidil was encapsulated in the nanocarriers and the in vivo biological effect was compared with a conventional dosage form. Minoxidil-loaded liquid crystal nanocarrier was able to selectively reach the pilosebaceous follicle, thus allowing an increased biological effectiveness of the delivered active in terms of biological response, duration of the biological effects, and reduction of collaterals. Our investigation showed that liquid crystal nanocarriers represent a promising device for the treatment of different pilosebaceous follicular impairments/diseases.

Indexed as

alopeciain vitroin vivoliquid crystal nanocarriersminoxidilpilosebaceous follicletopical drug deliverytransfollicular

Identifiers

PMID33266444
PMCPMC7700400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.